SYLVANT® (siltuximab):
Anti–IL‑6 treatment to help neutralize a cytokine storm

How SYLVANT Works

SYLVANT® (siltuximab) is the only FDA-approved treatment for idiopathic multicentric Castleman disease (iMCD)*

Learn More
*SYLVANT is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Clinical
Presentation
of iMCD

Learn More

How
SYLVANT
Works

Watch MOA Video

Diagnosing
iMCD

Learn More

Dosing and
Administration

Administering SYLVANT

Patient Connect
Can Help

Learn About Patient Services

Contact
a Rep

Get in Touch
Abbreviations: FDA, US Food and Drug Administration; IL-6, interleukin-6.